Gender Differences in microRNA Expressions as Related to Long-Term Graft Function in Kidney Transplant Patients
Abstract
:1. Introduction
2. Results
2.1. Patient Characteristics
2.2. Renal Function
2.3. Immune Factors
2.4. Differently Expressed miRNAs
3. Discussion
4. Patients and Methods
4.1. Data and Participants
4.2. Serological Assessment
4.3. Statistical Analysis
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Thurlow, J.S.; Joshi, M.; Yan, G.; Norris, K.C.; Agodoa, L.Y.; Yuan, C.M.; Nee, R. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am. J. Nephrol. 2021, 52, 98–107. [Google Scholar] [CrossRef] [PubMed]
- Wong, C.-Y. Current advances of stem cell-based therapy for kidney diseases. World J. Stem Cells 2021, 13, 914. [Google Scholar] [CrossRef]
- Gadi, N.; Wu, S.C.; Spihlman, A.P.; Moulton, V.R. What’s sex got to do with COVID-19? Gender-based differences in the host immune response to coronaviruses. Front. Immunol. 2020, 2147. [Google Scholar] [CrossRef] [PubMed]
- Florijn, B.W.; Bijkerk, R.; Kruyt, N.D.; van Zonneveld, A.J.; Wermer, M.J.H. Sex-Specific MicroRNAs in Neurovascular Units in Ischemic Stroke. Int. J. Mol. Sci. 2021, 22, 11888. [Google Scholar] [CrossRef] [PubMed]
- Fagundes, B.O.; de Sousa, T.R.; Nascimento, A.; Fernandes, L.A.; Sgnotto, F.D.R.; Orfali, R.L.; Aoki, V.; Duarte, A.J.D.S.; Sanabani, S.S.; Victor, J.R. IgG from Adult Atopic Dermatitis (AD) Patients Induces Nonatopic Neonatal Thymic Gamma–Delta T Cells (γδT) to Acquire IL-22/IL-17 Secretion Profile with Skin-Homing Properties and Epigenetic Implications Mediated by miRNA. Int. J. Mol. Sci. 2022, 23, 6872. [Google Scholar] [CrossRef] [PubMed]
- Jonas, M.I.; Kuryłowicz, A.; Bartoszewicz, Z.; Lisik, W.; Jonas, M.; Kozniewski, K.; Puzianowska-Kuznicka, M. Vitamin D receptor gene expression in adipose tissue of obese individuals is regulated by miRNA and correlates with the pro-inflammatory cytokine level. Int. J. Mol. Sci. 2019, 20, 5272. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jia, Y.; Wei, Y. Modulators of MicroRNA function in the immune system. Int. J. Mol. Sci. 2020, 21, 2357. [Google Scholar] [CrossRef] [PubMed]
- Winger, E.E.; Reed, J.L.; Ji, X. First-trimester maternal cell microRNA is a superior pregnancy marker to immunological testing for predicting adverse pregnancy outcome. J. Reprod. Immunol. 2015, 110, 22–35. [Google Scholar] [CrossRef] [PubMed]
- Alfaro, R.; Legaz, I.; Jimenez-Coll, V.; Band, J.E.K.E.; Martínez-Banaclocha, H.; Galián, J.; Parrado, A.; Mrowiec, A.; Botella, C.; Moya-Quiles, M.; et al. MicroRNA Expression Changes in Kidney Transplant: Diagnostic Efficacy of miR-150-5p as Potential Rejection Biomarker, Pilot Study. J. Clin. Med. 2021, 10, 2748. [Google Scholar] [CrossRef]
- Di Palo, A.; Siniscalchi, C.; Salerno, M.; Russo, A.; Gravholt, C.H.; Potenza, N. What microRNAs could tell us about the human X chromosome. Cell. Mol. Life Sci. 2020, 77, 4069–4080. [Google Scholar] [CrossRef] [PubMed]
- Piscopo, P.; Bellenghi, M.; Manzini, V.; Crestini, A.; Pontecorvi, G.; Corbo, M.; Ortona, E.; Carè, A.; Confaloni, A. A sex perspective in neurodegenerative diseases: microRNAs as possible peripheral biomarkers. Int. J. Mol. Sci. 2021, 22, 4423. [Google Scholar] [CrossRef]
- Lopes-Ramos, C.M.; Chen, C.-Y.; Kuijjer, M.L.; Paulson, J.N.; Sonawane, A.R.; Fagny, M.; Platig, J.; Glass, K.; Quackenbush, J.; DeMeo, D.L. Sex differences in gene expression and regulatory networks across 29 human tissues. Cell Rep. 2020, 31, 107795. [Google Scholar] [CrossRef] [PubMed]
- Trabzuni, D.; North American Brain Expression Consortium; Ramasamy, A.; Imran, S.; Walker, R.; Smith, C.; Weale, M.; Hardy, J.; Ryten, M. Widespread sex differences in gene expression and splicing in the adult human brain. Nat. Commun. 2013, 4, 2771. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pontrelli, P.; Grandaliano, G.; Van Kooten, C. Kidney Transplantation and Innate Immunity. Front. Immunol. 2020, 11, 603982. [Google Scholar] [CrossRef] [PubMed]
- Pontrelli, P.; Rascio, F.; Castellano, G.; Grandaliano, G.; Gesualdo, L.; Stallone, G. The role of natural killer cells in the immune response in kidney transplantation. Front. Immunol. 2020, 11, 1454. [Google Scholar] [CrossRef] [PubMed]
- Pinheiro, I.; Dejager, L.; Libert, C. X-chromosome-located microRNAs in immunity: Might they explain male/female differences? The X chromosome-genomic context may affect X-located miRNAs and downstream signaling, thereby contributing to the enhanced immune response of females. Bioessays 2011, 33, 791–802. [Google Scholar] [CrossRef]
- Xia, Z.; Meng, F.; Liu, Y.; Fang, Y.; Wu, X.; Zhang, C.; Liu, D.; Li, G. Decreased MiR-128-3p alleviates the progression of rheumatoid arthritis by up-regulating the expression of TNFAIP3. Biosci. Rep. 2018, 38. [Google Scholar] [CrossRef] [Green Version]
- Xiaokelaiti, H.; Zhi, X.; Yusufujiang, Y.; Aikebaier, A. miR-128-3p regulates inflammatory response in LPS-stimulated macrophages through the TLR4-NF-κB pathway. Int. J. Clin. Exp. Med. 2016, 9, 8005–8013. [Google Scholar]
- Smith, N.L.; Wissink, E.; Grimson, A.; Rudd, B.D. miR-150 regulates differentiation and cytolytic effector function in CD8+ T cells. Sci. Rep. 2015, 5, 16399. [Google Scholar] [CrossRef] [Green Version]
- Xiao, C.; Calado, D.P.; Galler, G.; Thai, T.-H.; Patterson, H.C.; Wang, J.; Rajewsky, N.; Bender, T.P. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 2007, 131, 146–159. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hippen, K.L.; Loschi, M.; Nicholls, J.; MacDonald, K.P.A.; Blazar, B.R. Effects of microRNA on regulatory T cells and implications for adoptive cellular therapy to ameliorate graft-versus-host disease. Front. Immunol. 2018, 9, 57. [Google Scholar] [CrossRef] [PubMed]
- Jiao, P.; Wang, X.-P.; Luoreng, Z.-M.; Yang, J.; Jia, L.; Ma, Y.; Wei, D.-W. miR-223: An effective regulator of immune cell differentiation and inflammation. Int. J. Biol. Sci. 2021, 17, 2308–2322. [Google Scholar] [CrossRef]
- Johnnidis, J.B.; Harris, M.H.; Wheeler, R.T.; Stehling-Sun, S.; Lam, M.H.; Kirak, O.; Brummelkamp, T.R.; Fleming, M.; Camargo, F.D. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 2008, 451, 1125–1129. [Google Scholar] [CrossRef] [PubMed]
- Tang, H.-C.; Lai, Y.-Y.; Zheng, J.; Jiang, H.-Y.; Xu, G. miR-223-3p inhibits antigen endocytosis and presentation and promotes the tolerogenic potential of dendritic cells through targeting mannose receptor signaling and rhob. J. Immunol. Res. 2020, 2020, 1379458. [Google Scholar] [CrossRef]
- Zhang, Q.-B.; Zhu, D.; Dai, F.; Huang, Y.-Q.; Zheng, J.-X.; Tang, Y.-P.; Dong, Z.-R.; Liao, X.; Qing, Y.-F. MicroRNA-223 suppresses IL-1β and TNF-α production in gouty inflammation by targeting the NLRP3 inflammasome. Front. Pharmacol. 2021, 550. [Google Scholar] [CrossRef]
- Yang, Q.; Xu, H.; Yang, J.; Zhou, Y.; Zhao, D.; Liu, F. MicroRNA-223 affects IL-6 secretion in mast cells via the IGF1R/PI3K signaling pathway. Int. J. Mol. Med. 2016, 38, 507–512. [Google Scholar] [CrossRef] [Green Version]
- Miller, C.L.; Madsen, J.C. IL-6 directed therapy in transplantation. Curr. Transplant. Rep. 2021, 8, 191–204. [Google Scholar] [CrossRef] [PubMed]
- Xie, Q.; Wei, M.; Kang, X.; Liu, D.; Quan, Y.; Pan, X.; Liu, X.; Liao, D.; Liu, J.; Zhang, B. Reciprocal inhibition between miR-26a and NF-κB regulates obesity-related chronic inflammation in chondrocytes. Biosci. Rep. 2015, 35, e00204. [Google Scholar] [CrossRef]
- Chen, Y.; Zhou, X.; Wu, Y. The miR-26a-5p/IL-6 axis alleviates sepsis-induced acute kidney injury by inhibiting renal inflammation. Ren. Fail. 2022, 44, 551–561. [Google Scholar] [CrossRef]
- Li, X.; Pan, X.; Fu, X.; Yang, Y.; Chen, J.; Lin, W. MicroRNA-26a: An emerging regulator of renal biology and disease. Kidney Blood Press. Res. 2019, 44, 287–297. [Google Scholar] [CrossRef]
- Liang, S.; Wang, W.; Gou, X. MicroRNA 26a modulates regulatory T cells expansion and attenuates renal ischemia–reperfusion injury. Mol. Immunol. 2015, 65, 321–327. [Google Scholar] [CrossRef]
Female | Male | p-Value | |||
---|---|---|---|---|---|
Control | Dysfunction | Control | Dysfunction | ||
n = 5 | n = 12 | n = 15 | n = 8 | ||
Age (years) | 58.3 ± 5.4 | 55.5 ± 10.4 | 54.3 ± 9.8 | 49.1 ± 11.5 | 0.42 |
Age of KTx (years) | 39.1 ± 5.5 | 37.1 ± 11.4 | 37.4 ± 12.3 | 34.3 ± 13.4 | 0.90 |
Vintage of KTx (years) | 19.2 ± 6.1 | 18.4 ± 3.9 | 16.9 ± 4.0 | 14.8 ± 2.8 | 0.15 |
BUN (mg/dL) | 13.6 ± 2.7 | 25.9 ± 10.1 | 16.3 ± 5.7 | 20.6 ± 3.3 | 0.002 |
Cr (mg/dL) | 0.9 ± 0.1 | 1.5 ± 0.3 | 1.1 ± 0.1 | 1.7 ± 0.3 | <0.001 |
eGFR (ml/min) | 72.0 ± 9.0 | 40.8 ± 9.5 | 75.2 ± 7.2 | 48.6 ± 7.2 | <0.001 |
UPCR (mg/mg) | 101.2 ± 48.5 | 931.7 ± 2171.1 | 135.8 ± 83.9 | 316.9 ± 285.1 | 0.10 |
Plat (×103/μL) | 213.4 ± 27.6 | 246.9 ± 59.1 | 221.5 ± 63.4 | 229.9 ± 55.9 | 0.73 |
Hb (gm/dL) | 13.8 ± 0.8 | 11.8 ± 1.5 | 14.1 ± 1.8 | 13.8 ± 1.4 | 0.01 |
WBC (/μL) | 7162.0 ± 1900.2 | 7517.5 ± 2237.8 | 7012.7 ± 907.7 | 7433.8 ± 1436.8 | 0.78 |
NK (%) | 18(17–19) | 16 (9–23) | 19 (1–28) | 12 (5–19) | 0.32 |
N/L ratio | 2.0 (1.1–2.9) | 2.9 (1.0–5.0) | 2.6 (0.9–4.4) | 3.7 (0.3–7.1) | 0.60 |
P/L ratio (×1000) | 6.9 (5.4–8.4) | 10.7 (3.5–14.3) | 8.7 (5.3–12.2) | 11.0 (5.5–16.5) | 0.80 |
T cell (%) | 70 (58–82) | 73 (67–79) | 70 (61–79) | 77 (65–89) | 0.49 |
Activated T (%) | 5 (3–7) | 10 (4–16) | 8 (5–11) | 13 (1–25) | 0.34 |
LEU-3A (%) | 43 (38–48) | 38 (28–48) | 39 (29–49) | 41 (35–47) | 0.91 |
LEU-3A (μL−1) | 969.8 ± 362.7 | 692.2 ± 233.3 | 762.4 ± 425.7 | 719.6 ± 366.4 | 0.60 |
LEU-2B (%) | 27 (18–36) | 33 (23–43) | 30 (19–41) | 34 (23–45) | 0.45 |
LEU-2B (μL−1) | 504.3 ± 335.9 | 650.6 ± 256.3 | 574.0 ± 291.4 | 615.3 ± 417.5 | 0.91 |
B-cell (%) | 11 (5–17) | 9 (3–15) | 9 (3–15) | 9 (1–17) | 0.84 |
TH/TS (CD4/CD8) | 1.7 (1.2–2.3) | 1.4 (0.5–2.2) | 1.5 (0.9–2.1) | 1.4 (0.7–2.0) | 0.45 |
C3 (mg/dL) | 109.5 ± 15.0 | 111.5 ± 21.6 | 113.8 ± 23.0 | 122.2 ± 20.0 | 0.41 |
C4 (mg/dL) | 28.8 ± 8.6 | 28.8 ± 5.8 | 29.5 ± 11.2 | 31.2 ± 13.6 | 0.98 |
CH50 (CAE) | 101.33 ± 28.59 | 126.5 ± 3.54 | 108.88 ± 20.91 | 119.2 ± 22.11 | 0.66 |
IgG (mg/dL) | 1113.6 ± 157.1 | 1228.7 ± 298.2 | 1135.3 ± 246.6 | 1119.8 ± 191.7 | 0.91 |
IgA (mg/dL) | 320.5 ± 96.3 | 343.8 ± 230.2 | 249.8 ± 106.4 | 216.3 ± 92.7 | 0.32 |
IgM (mg/dL) | 97.5 ± 30.4 | 136.1 ± 61.6 | 89.2 ± 38.7 | 98.6 ± 56.6 | 0.28 |
FK-506 (ng/mL) | 5.1 ± 0.9 | 5.7 ± 0.9 | 5.1 ± 1.2 | 5.7 ± 1.3 | 0.57 |
Adagraf/prograf (mg/day) | 3 ± 1.5 | 6.4 ± 2.4 | 3.7 ± 2.0 | 5.1 ± 3.6 | 0.03 |
Numbers | Mean Ct | log2ratio | p-Value | |||
---|---|---|---|---|---|---|
microRNA ID | Control n = 5 | Dysfunction n = 12 | Control | Dysfunction | ||
miR-128-3p | 2 | 8 | 32.272 | 29.315 | 2.957 | 0.0063 |
miR-21-5p | 5 | 12 | 26.251 | 27.059 | −0.808 | 0.0113 |
miR-150-5p | 5 | 12 | 26.905 | 27.953 | −1.048 | 0.0133 |
miR-92a-3p | 5 | 12 | 22.533 | 23.974 | −1.441 | 0.0172 |
miR-15a-5p | 5 | 12 | 27.119 | 28.483 | −1.364 | 0.0278 |
Number | Mean Ct | log2ratio | p-Value | |||
---|---|---|---|---|---|---|
microRNA ID | Control n = 15 | Dysfunction n = 8 | Control | Dysfunction | ||
miR-23a-3p | 15 | 8 | 28.139 | 29.422 | −1.283 | 0.0222 |
miR-126-3p | 15 | 8 | 27.396 | 28.147 | −0.751 | 0.0321 |
miR-142-3p | 15 | 8 | 27.778 | 28.504 | −0.726 | 0.0357 |
miR-223-3p | 15 | 8 | 25.728 | 26.375 | −0.647 | 0.0388 |
miR-26a-5p | 15 | 7 | 28.867 | 30.516 | −1.649 | 0.0395 |
Expression in Dysfunction Groups | Functions | ||
---|---|---|---|
Female | Male | ||
MiR-128-3p | Upregulation | - | Proinflammation: Induces IL-6 and IL-17 production |
MiR-150-5p | Downregulation | - | Anti-inflammation: Inhibits CD8+ T cells and mTOR, stimulates Treg differentiation |
MiR-223-3p | - | Downregulation | Anti-inflammation: Suppresses TRAF6, NF-κB and IGF1R/PI3K pathway, reduces IL-6 secretion |
MiR-26a | - | Downregulation | Anti-inflammation: stimulates Tregs/CD4+ T cells ratio, reduces IL-6 secretion |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ko, S.-Y.; Tsai, S.-F.; Hsu, C.-T.; Huang, S.-T.; Chuang, Y.-W.; Yu, T.-M.; Wu, M.-J.; Chen, C.-H. Gender Differences in microRNA Expressions as Related to Long-Term Graft Function in Kidney Transplant Patients. Int. J. Mol. Sci. 2022, 23, 12832. https://doi.org/10.3390/ijms232112832
Ko S-Y, Tsai S-F, Hsu C-T, Huang S-T, Chuang Y-W, Yu T-M, Wu M-J, Chen C-H. Gender Differences in microRNA Expressions as Related to Long-Term Graft Function in Kidney Transplant Patients. International Journal of Molecular Sciences. 2022; 23(21):12832. https://doi.org/10.3390/ijms232112832
Chicago/Turabian StyleKo, Sien-Yu, Shang-Feng Tsai, Chia-Tien Hsu, Shih-Ting Huang, Ya-Wen Chuang, Tung-Min Yu, Ming-Ju Wu, and Cheng-Hsu Chen. 2022. "Gender Differences in microRNA Expressions as Related to Long-Term Graft Function in Kidney Transplant Patients" International Journal of Molecular Sciences 23, no. 21: 12832. https://doi.org/10.3390/ijms232112832